Thomas Simmerer takes over sales at Carl Zeiss Meditec
Succeeds Ulrich Krauss as member of the management board with responsibility for sales
‘I am looking forward to my new responsibilities and will maintain and expand the successful sales and service structure at Carl Zeiss Meditec in the respective markets,’ said Simmerer.
Simmerer has extensive experience in medical technology. He was in charge of the Microsurgery strategic business unit in Oberkochen from October 2008. Before joining the medical wing of Carl Zeiss, the mechanical engineer led the top-performing business unit, among others, of Dräger Medical in Lübeck from 1996 to 2008. Prior to this, he was responsible for different sales areas at Heraeus in Hanau.
You may also like
Pharma 5.0
ZEISS and Concept Life Sciences partner to advance automated workflows and AI-powered image analysis in spatial biology
The collaboration focusses on high-throughput imaging, AI-driven data analysis and streamlined integration into lab systems, aiming to improve efficiency and data quality for areas such as drug discovery and cancer research
Research & Development
Medicines Discovery Catapult and ZEISS set sights on advancing microscopy in drug discovery
Medicines Discovery Catapult (MDC) and ZEISS have joined forces to improve drug discovery and early development of complex medicines by harnessing the power of advanced microscopy solutions
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development
Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures
A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models